Genus plc
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jorgen Kokke
- Full Time Employees
- 3,500
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Matrix House Basingstoke United Kingdom RG21 4DZ
- IPO Date
- Sep 11, 2009
- Website
- genusplc.com
- Similar Companies
- Business
- Genus plc Genus plc develops and commercializes advanced animal genetics and biotechnology solutions for the global livestock industry, focusing on swine, dairy cattle and beef cattle to enhance productivity, sustainability and disease resistance. The company operates through two primary divisions, Genus PIC, which supplies genetically superior breeding pigs, porcine semen and technical services to pork producers; and Genus ABS, which provides bovine semen including sexed varieties, embryos from elite dairy and beef bulls, and associated advisory services to enable artificial insemination for improved milk yield, fertility and meat quality. Genus Research and Development supports these businesses with genomic selection, proprietary technologies such as sexed semen sorting and gene editing innovations like the PRRS-resistant pig, alongside comprehensive farmer support including data analytics and herd management advice; the company serves farmers and food producers across more than 85 countries on six continents through direct operations in 30 nations and distribution networks elsewhere. Founded as a predecessor entity in 1933 and incorporated in its current form in 1994, Genus plc maintains global headquarters in Basingstoke, United Kingdom, with key facilities including research laboratories in Madison, Wisconsin, USA, and major operational hubs in DeForest, Wisconsin, and Hendersonville, Tennessee. In recent strategic developments, Genus plc achieved U.S. Food and Drug Administration approval in April 2025 for its PRRS-resistant pig gene edit, advancing commercialization efforts in the U.S. and pursuing approvals in Canada, Mexico and Japan; the company completed Phase 2 of its ABS Value Acceleration Programme delivering annualized operating profit benefits of £10 million with Phase 3 initiatives targeting an additional £9 million; and in September 2025 announced accelerated formation of a porcine joint venture in China with Beijing Capital Agribusiness, under which BCA acquires 51% ownership for a gross cash payment of US$160 million plus US$7.5 million in milestones, with PIC China deconsolidated and Genus retaining 49% equity alongside intellectual property royalties on PRRS-resistant pig sales.
Genus Power Surpasses 26 Million Smart Meter Deployment Worldwide, Reinforcing Leadership in End-to-End Advanced Metering Solutions
Genus plc (GENSY) Q2 2026 Earnings Call Transcript
Genus growth prospects look healthy, says broker
Bank lifts Genus target to 3300p on strong PIC trading in China and Latin America
UK animal genetics firm Genus surges on annual profit forecast upgrade
Genus extends Friday rally as brokers lift forecasts after ahead-of-expectations update
Genus (OTCMKTS:GENSF) Trading 5.1% Higher – Still a Buy?
Genus boosts shares by raising profit outlook after strong China pig sales
Genus Plc (GENSY) Q4 2025 Earnings Call Prepared Remarks Transcript
Genus jumps 11% as new Chinese pig JV formed at end of 'landmark' year
British animal genetics firm Genus surges on strong annual profit growth
Broker lifts target price for Genus as turnaround gathers pace
Genus up 7% after strong trading update; broker reckons there's further to go
Genus FDA green light a “hugely significant landmark"
UK's Genus secures FDA approval for PRP gene edit; shares soar
Genus shares leap 22% after FDA clears gene-edited pigs for US food chain
Genus plc (GENSF) Q2 2025 Earnings Call Transcript
Genus rises 20% after trading exceeds expectations
Genus rebounds on update after Trump and RFK worries hit shares